MX2009011247A - Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones. - Google Patents

Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones.

Info

Publication number
MX2009011247A
MX2009011247A MX2009011247A MX2009011247A MX2009011247A MX 2009011247 A MX2009011247 A MX 2009011247A MX 2009011247 A MX2009011247 A MX 2009011247A MX 2009011247 A MX2009011247 A MX 2009011247A MX 2009011247 A MX2009011247 A MX 2009011247A
Authority
MX
Mexico
Prior art keywords
biologically active
nanoparticles
active molecule
cyclodextrin
molecules
Prior art date
Application number
MX2009011247A
Other languages
English (en)
Inventor
Maite Agueeros Bazo
Hesham H A Salman
Juan Manuel Irache Garreta
Miguel Angel Campanero Martinez
Original Assignee
Inst Cientifico Tecnol Navarra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Cientifico Tecnol Navarra filed Critical Inst Cientifico Tecnol Navarra
Publication of MX2009011247A publication Critical patent/MX2009011247A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Medical Informatics (AREA)
  • Physiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Las nanopartículas comprenden un polímero biodegradable, una ciclodextrina o un derivado de la misma, y una molécula biológicamente activa. Dichas nanopartículas pueden asociar elevadas cantidades de moléculas biológicamente activas, especialmente, de naturaleza hidrófoba, y liberar la molécula biológicamente activa proporcionando unos niveles plasmáticos sostenidos y constantes de la misma cuando son administradas por vía oral o a través de cualquier otra mucosa del organismo.
MX2009011247A 2007-04-20 2008-04-18 Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones. MX2009011247A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200701074A ES2310122B1 (es) 2007-04-20 2007-04-20 Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones.
PCT/ES2008/000269 WO2008129106A2 (es) 2007-04-20 2008-04-18 Nanopartículas que comprenden una ciclodextrina y una molécula biológicamente activa y sus aplicaciones

Publications (1)

Publication Number Publication Date
MX2009011247A true MX2009011247A (es) 2010-01-29

Family

ID=39643881

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011247A MX2009011247A (es) 2007-04-20 2008-04-18 Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones.

Country Status (11)

Country Link
US (1) US9522197B2 (es)
EP (1) EP2153826B1 (es)
JP (1) JP5847397B2 (es)
CN (1) CN101686949A (es)
AU (1) AU2008240545B2 (es)
BR (1) BRPI0810396A2 (es)
CA (1) CA2684560C (es)
ES (2) ES2310122B1 (es)
MX (1) MX2009011247A (es)
RU (1) RU2460518C2 (es)
WO (1) WO2008129106A2 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014277744B2 (en) * 2010-04-16 2017-01-19 Cumberland Pharmaceuticals, Inc. Stabilized Statin Formulations
US8372877B2 (en) * 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
EA016410B1 (ru) * 2010-11-13 2012-04-30 Ооо "Нпк Наносистема" Фармацевтическая композиция на основе наночастиц циклодекстрина, содержащих рифабутин, способ ее получения, способ лечения микобактериоза и геликобактерной инфекции (варианты)
WO2012138731A2 (en) * 2011-04-04 2012-10-11 Board Of Regents Of The University Of Nebraska Activated nucleoside analog conjugates and methods of use thereof
EP2510930A1 (en) 2011-04-15 2012-10-17 Bionanoplus, S.L. Nanoparticles comprising half esters of poly (methyl vinyl ether-co-maleic anhydride) and uses thereof
JP5391229B2 (ja) * 2011-04-27 2014-01-15 富士フイルム株式会社 木構造抽出装置および方法ならびにプログラム
CN102670513B (zh) * 2012-02-22 2014-03-19 河南碧云天动物药业有限公司 氧氟沙星分子包合纳米制剂及其制备方法
CN104244986B (zh) * 2012-03-13 2016-11-16 浦项工科大学校产学协力团 可控释的药物递送缀合物及其应用
CN102579402B (zh) * 2012-03-26 2013-07-03 山东大学 一种负载紫杉醇的囊泡的制备方法
US8916697B2 (en) * 2012-03-30 2014-12-23 Purdue Research Foundation Nucleic acid complexes
WO2014064637A1 (en) * 2012-10-26 2014-05-01 Lupin Limited Stable pharmaceutical composition of tnfr:fc fusion protein
FR3000080B1 (fr) * 2012-12-20 2015-01-30 Oreal Polycondensat de cyclodextrine insoluble dans l'eau ; utilisations comme agent de capture
CN103142499B (zh) * 2013-03-21 2014-10-01 青岛正大海尔制药有限公司 一种依托泊苷颗粒
CN103705987B (zh) * 2014-01-02 2015-10-07 东南大学 一种具有ct造影功能的葡聚糖栓塞微球的制备方法
RU2546535C1 (ru) * 2014-04-09 2015-04-10 Федеральное государственное бюджетное учреждение науки Институт химии твердого тела и механохимии Сибирского отделения Российской академии наук (ИХТТМ СО РАН) Противопаразитарное средство на основе альбендазола и способ его использования для лечения гельминтозов млекопитающих
KR20170023173A (ko) * 2014-07-03 2017-03-02 화이자 인코포레이티드 표적화된 치료 나노입자 및 그의 제조 및 사용 방법
CN104387592B (zh) * 2014-11-29 2017-09-26 沈阳药科大学 环糊精‑甲基乙烯基醚/马来酸酐共聚物及其自组装纳米粒在口服药物传递中应用
PT3233126T (pt) 2014-12-01 2019-05-27 Innoup Farma S L Nanopartículas para encapsular compostos, sua preparação e utilizações
CN105194687A (zh) * 2015-10-22 2015-12-30 浙江医药高等专科学校 沙喹那韦或其甲磺酸盐的环糊精包合物制备方法
CN105561406A (zh) * 2016-02-15 2016-05-11 丹阳纳瑞康纳米科技有限公司 一种含复合药物涂层的血管支架
CN105695148B (zh) * 2016-02-24 2018-11-02 江阴市佐恩精品衣物洗涤护理有限公司 一种环保型固体清洗剂组合物
US10626165B2 (en) 2016-12-14 2020-04-21 Janssen Biotech, Inc. CD8a-binding fibronectin type III domains
US10800817B2 (en) 2016-12-19 2020-10-13 Morehouse School Of Medicine Compositions and methods for treating diseases by inhibiting exosome release
CN109602724B (zh) * 2019-02-21 2022-02-11 江苏省中医药研究院 一种牛蒡子苷元口服纳米制剂及其制备方法
JP7258351B2 (ja) 2019-09-13 2023-04-17 株式会社菊水製作所 回転式粉体圧縮成形機
JP2022551204A (ja) 2019-10-14 2022-12-07 アロ・バイオセラピューティクス・カンパニー Ｃｄ７１結合フィブロネクチンｉｉｉ型ドメイン
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
CN110898015A (zh) * 2019-12-31 2020-03-24 上海汉维生物医药科技有限公司 一种伊曲康唑制剂的制备方法
CN113777100B (zh) * 2021-08-27 2022-11-01 厦门大学 一种基于主客体作用的定量物质控释系统及方法
CN114053229B (zh) * 2022-01-17 2022-04-22 山东国邦药业有限公司 一种盐酸沙拉沙星水溶性颗粒剂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU213200B (en) * 1993-05-12 1997-03-28 Chinoin Gyogyszer Es Vegyeszet The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
US6515016B2 (en) * 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
FR2775435B1 (fr) * 1998-02-27 2000-05-26 Bioalliance Pharma Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs
CA2429254A1 (en) * 2000-11-20 2002-05-30 James M. Dunn Oral nanosphere delivery
ES2178961B1 (es) 2001-03-06 2004-07-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Fabricacion de nanoparticulas a base del copolimero de metil vinil eter y anhidrido maleico para la administracion de farmacos de naturaleza hidrofilica, en particular de bases puricas y pirimidinicas.
FR2830017B1 (fr) * 2001-09-27 2005-11-04 Centre Nat Rech Scient Materiau compose d'au moins un polymere biodegradable et de cyclodextrines
GB0127677D0 (en) * 2001-11-19 2002-01-09 Vianex S A Inclusion complex
ES2246694B1 (es) * 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
ES2277743B2 (es) * 2005-06-02 2008-12-16 Universidade De Santiago De Compostela Nanoparticulas que comprenden quitosano y ciclodextrina.

Also Published As

Publication number Publication date
ES2310122B1 (es) 2009-10-30
ES2684554T3 (es) 2018-10-03
EP2153826A2 (en) 2010-02-17
CA2684560C (en) 2016-06-14
CN101686949A (zh) 2010-03-31
AU2008240545B2 (en) 2013-06-06
JP5847397B2 (ja) 2016-01-20
ES2310122A1 (es) 2008-12-16
WO2008129106A3 (es) 2009-03-05
EP2153826B1 (en) 2018-06-27
RU2009142806A (ru) 2011-05-27
JP2010524902A (ja) 2010-07-22
RU2460518C2 (ru) 2012-09-10
CA2684560A1 (en) 2008-10-30
AU2008240545A1 (en) 2008-10-30
US20100136129A1 (en) 2010-06-03
US9522197B2 (en) 2016-12-20
BRPI0810396A2 (pt) 2014-11-04
WO2008129106A2 (es) 2008-10-30

Similar Documents

Publication Publication Date Title
MX2009011247A (es) Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones.
WO2008124735A3 (en) Multi-functional polyglutamate drug carriers
WO2008141110A3 (en) Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs
WO2008094834A3 (en) Multi-functional drug carriers
HK1146075A1 (en) Polyglutamate-amino acid conjugates and methods
MX2009005727A (es) Nanoparticulas de entidad anfifilica.
AR061785A1 (es) Nanoparticulas de quitosano e hialuronano para la administracion de moleculas activas
WO2008085556A3 (en) Surfactant-free nanoparticles for drug delivery
WO2006097558A3 (es) Nanopartículas de quitosano y polientilenglicol como sistema de administración de moléculas biológicamente activas
WO2007148230A3 (en) Grafted polymers and uses thereof
TW200640498A (en) Suspending vehicles and pharmaceutical suspensions for drug dosage forms
WO2007150030A3 (en) Microfluidic synthesis of organic nanoparticles
CY1113824T1 (el) Ενδορινικες συνθεσεις
ATE502658T1 (de) Polymer-komposit-stent mit polymerteilchen
WO2009041666A1 (ja) 葉酸修飾されたシクロデキストリン化合物、その製造方法、標的指向性薬物送達システム用の薬物送達剤、医薬組成物及び造影剤
GT200600097A (es) Formas farmaceuticas con propiedades farmacocineticas mejoradas
SI1909843T1 (sl) Protitumorski biokonjugati hialuronske kisline ali njenih derivatov, dobljeni z indirektno kemijsko konjugacijo, in njihova uporaba na farmacevtskem področju
MX2009010907A (es) Formulacion del agente activo cargado en nanoparticulas de plga activadas para nano-terapeuticos direccionados para el cancer.
NZ596876A (en) Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
MX347056B (es) Composiciones farmaceuticas.
WO2010131907A3 (ko) 자기 집합체 고분자 나노입자를 이용한 sirna 전달 시스템
WO2009130602A9 (en) Factor ix conjugates with extended half-lives
MX2009005696A (es) Nanoparticulas magneticas para la aplicacion en hipertermia, preparacion de las mismas y uso en constructos que tienen una aplicacion farmacologica.
WO2009010837A3 (en) Nanoparticles comprising a non-ionizable polymer and an anionic cellulosic polymer
DK1543063T3 (da) Medikament levering

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights